RxDoctor Payments Data

Tareq Harb, MD

Interventional Cardiology · Ogden, UTNPI 1407851488

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 34.2% of the total. Reporting peaked in 2023 at $11,292 and has fallen 93.1% since, to $782 in 2025.

$27,452in general payments, 2019–2025

Across 137 payments — averaging $200.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Shockwave Medical, Inc$8K
  • Penumbra, Inc.$6K
  • Cordis US CORP.$2K
  • Abbott$1K
  • Cook Medical LLC$250
  • plus $301 from 8 others

What the payments were for

  • Consulting fees$2501%
  • Speaking & faculty fees$6,60024%
  • Travel & lodging$13,95151%
  • Food & beverage$6,62824%
  • Education$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,452 in reported general payments places this provider in the 85th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah

Medicare billing

Part B allowed, 2024
$217,693
Medicare patients
1,261
Services billed
2,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$85,061
XareltoRivaroxaban16$24,026
Prasugrel Hcl151$14,777
BrilintaTicagrelor17$10,638
Repatha SureclickEvolocumab15$9,131
Ezetimibe150$3,346
Rosuvastatin Calcium205$3,337
Metoprolol Succinate228$3,197
ClopidogrelClopidogrel Bisulfate217$3,195
Atorvastatin Calcium195$2,167
Isosorbide Mononitrate ErIsosorbide Mononitrate159$1,778
Pantoprazole Sodium86$1,359
Losartan Potassium110$1,342
Nitroglycerin111$1,213
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$85,06161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 interventional cardiology providers in Utah.

Other interventional cardiology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →